Affiliation:
1. Center of Bowel Treatment, Brzeziny, Poland
2. Department of General and Colorectal Surgery, Medical University of Lodz, Poland
Abstract
Introduction:
Colorectal cancer is the most frequent neoplasm of the whole gastrointestinal track. Due to screening colonoscopy program, colorectal lesions are often diagnosed at early stage. The vast majority of them are possible to remove endoscopically. However, a substantial percentage of benign lesion in Western centers are still operated.
The aim of this article was to determine the percentage of surgical resections due to benign adenomas in the reference center of endoscopic submucosal dissection (ESD) and colorectal surgery in Poland.
Materials and Methods:
Retrospective analysis of 3 510 patients operated from 2015 to 2019 in Center of Bowel Treatment in Brzeziny.
Results:
We have analyzed 3 510 endoscopic and surgical procedures performed in the colon: 601 ESDs; 1 002 endoscopic mucosal resections (EMRs); and 1,907 surgical resections. Out of 601 ESDs, 57 invaded the submucosa, of which 29 (4.8%) were non-therapeutic ESDs. In 5 patients, due to occurrence of post-ESD perforation, an additional surgical intervention was necessary. Out of the 1,002 EMRs, 22 cases (2.2%) were diagnosed with deeply infiltrating cancers, which required a surgery. The overall percentage of the need for surgery in the endoscopically treated patients (ESD + mucosectomy) was 3.5% (56/1 603). Among resection surgeries, 15 of them (0.8%) ended with the diagnosis of a benign lesion in the postoperative histopathological examination.
Conclusions:
Inclusion advanced endoscopic techniques such as ESD to routine clinical practice in colorectal centers gives clear benefits for the patients. Well defined and standardized process of qualifying for appropriate treatment allows to significantly reduce the percentage of abdominal approach surgery due to benign colorectal lesions.
Reference65 articles.
1. American Cancer Society. 2021 [cytowane 29 stycznia 2021]. w: Cancer Statistics Center [Internet] Dostęp pod adresem: https://cancerstatisticscenter. cancer.org. Data dostępu: 23 stycznia 2021
2. Centers for Disease Control and Prevention: Vital signs: colorectal cancer screening test use – United States, 2012. MMWR Morb Mortal Wkly Rep., 2013; 62(44): 881–888.
3. Bibbins-Domingo K., Grossman D.C., Curry S.J. et al.: Screening for colorectal cancer: US Preventive Services Task Force Recommendation Statement. JAMA, 2016; 315: 2564–2575.
4. Wolf A.M.D., Fontham E.T.H., Church T.R. et al.: Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin., 2018; 68: 250–281.
5. Lin J.S., Piper M.A., Perdue L.A. et al.: Screening for Colorectal Cancer: A Systematic Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 135. Agency for Healthcare Research and Quality, Rockville, MD2015.